New blood test may predict bleeding danger for cancer patients on clot drugs
NCT ID NCT06386107
First seen Nov 24, 2025 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This study looks at whether a special blood test, called a thrombin generation assay, can predict bleeding risk in cancer patients who are taking blood thinners for blood clots. Researchers will follow 212 patients for 6 months, measuring their blood's clotting ability and tracking any bleeding events. The goal is to see if this test can help doctors choose safer treatments for cancer-associated thrombosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Grenoble
NOT_YET_RECRUITINGGrenoble, 38043, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Chu Clermont-Ferrand
NOT_YET_RECRUITINGClermont-Ferrand, 63003, France
Contact
Contact
Contact
Contact
Contact
Contact
-
Chu St-Etienne
RECRUITINGSaint-Etienne, 42055, France
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact
Contact
Contact
-
HCL
NOT_YET_RECRUITINGLyon, France
Contact
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Thrombin Generation Assay (blood test)
What this could lead to
If successful, this could lead to a blood test that helps doctors predict bleeding risk in cancer patients on anticoagulants, allowing safer treatment choices.
What could go wrong
This is an observational study, not a treatment trial. The test may not reliably predict bleeding, and results may not change clinical practice without further validation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.